Table 2.
Participant characteristics for women with anorexia nervosa (AN)/Atypical AN who are solely restricting (AN/AtypAN-R) versus those who restrict in combination with binge/purge behaviors (AN/AtypAN-BP).
| Characteristic | AN/AtypAN-R (n=21) |
AN/AtypAN-BP (n=32) |
p | Effect sizea |
|---|---|---|---|---|
| Age (years) | 25.0 (21.0-28.0) | 21.5 (19.5-33.0) | 0.636 | r=0.06 |
| Duration of illness (months)b | 8.0 (5.0-13.0) | 16.5 (11.0-27.5) | 0.004 | r=-0.41 |
| Lowest adult weight (kg) | 43.8 ± 5.8 | 42.8 ± 5.8 | 0.533 | g=0.17 |
| Weight (kg) | 49.9 ± 4.9 | 48.7 ± 5.4 | 0.417 | g=0.23 |
| BMI (kg/m2) | 18.5 ± 1.9 | 18.2 ± 1.4 | 0.548 | g=0.18 |
| %EBW | 83.9 ± 6.9 | 84.7 ± 7.5 | 0.730 | g=-0.11 |
| Amenorrheac | 6 (30.0) | 9 (28.1) | 1.000 | OR=1.10 |
| Current MDD | 10 (47.6) | 17 (53.1) | 0.782 | OR=0.80 |
| Current GAD | 15 (71.4) | 19 (59.4) | 0.400 | OR=1.71 |
| Current OCD | 1 (4.8) | 1 (3.1) | 1.000 | OR=1.55 |
| Current PTSD | 6 (28.6) | 7 (21.9) | 0.746 | OR=1.43 |
| Antidepressant medication | 14 (66.7) | 20 (62.5) | 1.000 | OR=1.20 |
| Anxiolytic medication | 10 (47.6) | 11 (34.4) | 0.397 | OR=1.74 |
| Mood stabilizers | 1 (4.8) | 3 (9.4) | 1.000 | OR=0.48 |
| Antipsychotic medication | 4 (19.1) | 3 (9.4) | 0.415 | OR=2.27 |
| Hypnotic medication | 1 (4.8) | 3 (9.4) | 1.000 | OR=0.48 |
| Melatonin | 2 (9.5) | 0 (0.0) | 0.152 | N/A |
| OCPsc | 8 (40.0) | 7 (21.9) | 0.213 | OR=2.38 |
| Estradiol (pg/mL)d | 76.6 ± 58.1 | 51.7 ± 53.8 | n/a | n/a |
| Ln-estradiold | 3.9 ± 1.3 | 3.3 ± 1.3 | 0.229 | g=0.42 |
| Fasting oxytocin (pg/mL) | 873 ± 534 | 1,013 ± 456 | n/a | n/a |
| Ln-oxytocin | 6.6 ± 0.5 | 6.8 ± 0.4 | 0.158 | g=-0.41 |
| EDE-Q Global Scoree | 2.8 ± 1.6 | 3.9 ± 1.1 | 0.025 | g=-0.75 |
| BDI Total Scoref | 19.3 ± 11.3 | 27.3 ± 9.5 | 0.032 | g=-0.74 |
| STAI Trait Score | 51.5 ± 11.7 | 55.4 ± 11.2 | 0.231 | g=-0.34 |
| TAS-20 Difficulty Identifying Feelings Scoreg | 19.0 ± 6.9 | 21.3 ± 6.1 | 0.216 | g=-0.35 |
| TAS-20 Difficulty Describing Feelings Scoreg | 15.1 ± 4.9 | 16.9 ± 4.5 | 0.185 | g=-0.38 |
| TAS-20 Externally Oriented Thinking Scoreg | 17.9 ± 4.9 | 18.6 ± 4.7 | 0.606 | g=-0.14 |
| TAS-20 Total Scoreg | 52.0 ± 13.1 | 56.9 ± 11.2 | 0.168 | g=-0.40 |
| LSAS-SR Social Fear Scoref | 14.7 ± 6.3 | 16.9 ± 5.2 | 0.261 | g=-0.37 |
| LSAS-SR Public Fear Scoref | 15.6 ± 6.4 | 19.4 ± 4.9 | 0.064 | g=-0.64 |
| LSAS-SR Social Avoidance Scoref | 13.4 ± 7.2 | 16.3 ± 6.4 | 0.218 | g=-0.41 |
| LSAS-SR Public Avoidance Scoref | 13.0 ± 7.1 | 16.7 ± 6.6 | 0.132 | g=-0.52 |
| DAPP-BQ Suspiciousness Scoref | 27.8 ± 8.9 | 34.4 ± 11.7 | 0.061 | g=-0.64 |
| DAPP-BQ Insecure Attachment Scoref | 36.3 ± 14.1 | 42.9 ± 16.2 | 0.207 | g=-0.43 |
| ISEL Total Scoref | 82.8 ± 17.8 | 68.9 ± 22.1 | 0.045 | g=0.69 |
Mean ± SD, median (IQR), or n (%). Significant values (p<0.05) are highlighted in bold. aEffect sizes are reported as Hedges’ g for group comparisons of normally distributed continuous variables analyzed with independent-sample t-tests, r for non-normally distributed variables analyzed with Mann-Whitney U-test, and OR (exact) for nominal variables analyzed with Fisher’s exact test. bFour participants with AN/AtypAN-BP did not provide information for duration of illness. cData available for 52 participants (20 participants with AN/AtypAN-R and 32 with AN/AtypAN-BP). dData available for 36 participants, all of whom were off OCP medication (12 participants with AN/AtypAN-R and 24 with AN/AtypAN-BP). eData available for 35 participants (21 participants with AN/AtypAN-R and 14 with AN/AtypAN-BP). fData available for 36 participants (21 participants with AN/AtypAN-R and 15 with AN/AtypAN-BP). gData available for 50 participants (21 participants with AN/AtypAN-R and 29 with AN/AtypAN-BP). BDI, Beck Depression Inventory-IA; BMI, body mass index; DAPP-BQ, Dimensional Assessment of Personality Pathology – Basic Questionnaire; %EBW, percent expected body weight; EDE-Q, Eating Disorder Examination Questionnaire; GAD, generalized anxiety disorder; ISEL, Interpersonal Support Evaluation List; LSAS-SR, Liebowitz Social Anxiety Scale; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; OCPs, oral contraceptive pills; PTSD, posttraumatic stress disorder; STAI, State-Trait Anxiety Inventory; TAS-20, Toronto Alexithymia Scale.